All patients applied 24 doses of imiquimod (Aldara, 3M Pharmaceuticals, St Paul, Minn) to the BCC lesion at night without occlusion. A 4-mm punch biopsy specimen was taken during the first 3 weeks of therapy to study the mechanism of action of imiquimod in BCC,2 and a final biopsy specimen was obtained 6 weeks after treatment to assess clearance of BCC. Patients whose BCCs had cleared after treatment were visited regularly for 5 years. The main outcome measures of the study were the intent-to-treat long-term clearance rate and the recurrence rate of the imiquimod-treated BCCs. We used the t test, χ2 test, Fisher exact test, and multivariate analyses in our statistical analysis (SPSS, version 11.5; SPSS Inc, Chicago, Ill).